Sherief Abd-Elsalam to Hepacivirus
This is a "connection" page, showing publications Sherief Abd-Elsalam has written about Hepacivirus.
Connection Strength
1.570
-
Hepatitis C Virus: Efficacy of New DAAs Regimens. Infect Disord Drug Targets. 2020; 20(2):143-149.
Score: 0.407
-
Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study. Environ Sci Pollut Res Int. 2018 Feb; 25(6):5459-5464.
Score: 0.352
-
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018 Jan; 163(1):51-56.
Score: 0.348
-
Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection. Infect Disord Drug Targets. 2020; 20(3):389-395.
Score: 0.102
-
Genetic Susceptibility in Family Members of Egyptian Hepatitis C Virus Infected Patients: Role of Interleukin-12 B Gene Polymorphism. Infect Disord Drug Targets. 2019; 19(1):81-87.
Score: 0.095
-
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice. Infect Disord Drug Targets. 2019; 19(2):179-184.
Score: 0.095
-
Association of IL-12 B Gene Polymorphism with Staging of Liver Disease in Chronic HCV Patients. Infect Disord Drug Targets. 2018; 18(2):122-128.
Score: 0.089
-
Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection. Infect Disord Drug Targets. 2017; 17(2):95-100.
Score: 0.083